About US
Contact us
>>Back
FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis
- Publisher：
- Publication：2011/6/7
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).
Previously, Aradigm received orphan drug designations from FDA for liposomal ciprofloxacin for inhalation for the management of bronchiectasis and for liposomal ciprofloxacin for the management of cystic fibrosis.
"We are very pleased that FDA has granted Aradigm this new orphan drug designation for bronchiectasis which provides additional incentive for our Company to develop a much needed therapeutic tool for this significant unmet medical need in respiratory medicine," said Igor Gonda, President and CEO.
Source: Aradigm Corporation